卓悅(00653.HK)計劃以不少於8億元售荃灣總部
卓悅控股(00653.HK)公布,於3月5日與買方就出售位於荃灣的卓悅集團中心訂立意向書,將向買方出售持有物業的附屬公司Apex Centric之全部已發行股本,建議出售代價不少於8億元。
卓悅指出,買方為獨立第三方,其身分將於訂立最終協議後的公告中公布,建議出售事項完成後,買方作為業主會將物業租回予集團,租期為三年。
公司指,建議出售事項將令卓悅能夠變現、並按公平市場價值體現物業的價值,所得款項淨額將加強公司現金流,提升營運資金狀況,以便重新分配用於業務發展的資源,包括發展全球零售商店及電商平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.